- Decrease font
- Increase font
- Send to a friend
Click here to bookmark this page
Customize your Bookmarks:
- Type the name of the page the way you would like it to appear in "My Bookmarks";
- Click in the "Add as My Bookmarks" button.
To choose your favorite sessions, please click here.
CENTRO DE IMAGEM DIAGNOSTICS S.A. ("Company") (B3: AALR3) ), in compliance with paragraph 4 of article 157 of Law 6404/76 and Instruction 44/2021 of the Brazilian Securities and Exchange Commission ("CVM"), informs its shareholders and the market in general that the Administrative Council for Economic Defense ("CADE") approved, on January 20, 2022, without restrictions, the transaction between Fonte de Saúde Fundo de Investimento em Participações Multiestratégia ("MAM") and signatories of the shareholders‘ agreement entered into on August 20, 2021, as amended ("Controlling Shareholders"), object of the Material Facts disclosed by the Company on November 18, 2021, November 26, 2021 and December 21, 2021 ("Transaction"). The decision will only be final after a period of 15 days from its publication in the Federal Official Gazette ("Diário Oficial da União"), which took place on this date, has elapsed, without any appeals by the CADE Court, under the terms of the applicable legislation. The closing of the Transaction still awaits the completion of other normal conditions precedent for this type of transaction, which will be communicated by the parties to the Company as soon as they are fulfilled.
The Company reiterates its commitment to keep the market informed about relevant facts and acts, in compliance with applicable regulations.
São Paulo, January 21, 2022.
To access the full document, click here.
CFO & IRO